Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jeffrey E. Rubnitz, MD,PhD
St. Jude Children's Research Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Phoenix Children'S Hospital
Phoenix, Arizona, United States
- Lucile Packard Children'S Hospital Stanford University
Palo Alto, California, United States
- University of Chicago
Chicago, Illinois, United States
- Duke University Medical Center
Durham, North Carolina, United States
- St. Jude Children'S Research Hospital
Memphis, Tennessee, United States
- Cook Children'S Medical Center
Fort Worth, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2014
- Primary completion
- 31 Dec 2015
- Completion
- 31 Dec 2015
- Last update posted
- 26 Mar 2020
- Registered enrollment
- 19
- Registry id
- NCT02212561
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.